Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse

详细信息    查看全文

• 作者：Saad S. Kenderian¹ ; ² ; David L. Porter³ ; ⁴ ; Saar Gill¹ ; ³ ; ⁴ ; ^{saar.gill@uphs.upenn.edu}
• 关键词：Chimeric antigen receptor T cells ; CART19 ; Immunotherapy ; Adoptive T cell therapy ; Adoptive immunotherapy ; Hematopoietic stem cell transplantation ; Bone marrow transplantation
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：23
• 期：2
• 页码：235-246
• 全文大小：1281 K
• 卷排序：23

文摘

Chimeric antigen receptor T (CART) cell therapy is an effective and potentially curative form of immunotherapy. CART cells can induce remissions as a bridge to allogeneic hematopoietic cell transplantation (allo-HCT) in B cell malignancies. In some patients, CART cells can induce sustained remission and replace allo-HCT. For patients relapsing after allo-HCT, CART cell therapy is a very effective option.